Search | Clinical Trials Finder

Conditions: Metastatic Melanoma
Interventions: Olaparib, Pembrolizumab; Drug
Lead sponsor: California Pacific Medical Center Research Institute; Other
Eligibility: 18 Years and older
Enrollment: 41 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 2
States / cities: San Francisco, California • Houston, Texas

Conditions: Prostate Cancer, Vitamin D Deficiency, Stress Reaction
Interventions: cholecalciferol, Standard of Care Prostate Biopsy - collection of 13th core for RNA-seq, Standard of Care Prostate Biopsies at baseline and after one year vitamin D3 supplementation, Allostatic Load; Drug · Procedure · Diagnostic Test
Lead sponsor: Medical University of South Carolina; Other
Eligibility: 50 Years to 75 Years · Male only
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2022
U.S. locations: 1
States / cities: Charleston, South Carolina

Conditions: Brain and Central Nervous System Tumors
Interventions: carboplatin, cisplatin, cyclophosphamide, etoposide, methotrexate, temozolomide, thiotepa, vincristine sulfate, autologous bone marrow transplantation, autologous hematopoietic stem cell transplantation, peripheral blood stem cell transplantation, radiation therapy; Drug · Procedure · Radiation
Lead sponsor: Children's Hospital Los Angeles; Other
Eligibility: Up to 10 Years
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2004
U.S. locations: 29
States / cities: Phoenix, Arizona • Loma Linda, California • Long Beach, California + 21 more

Conditions: NEC, Necrotizing Enterocolitis, Intestinal Disease, Human Development
Interventions: Not listed
Lead sponsor: Boston Children's Hospital; Other
Eligibility: Up to 2 Years
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2034
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Hypovitaminosis D
Interventions: Standing Phototherapy Kiosk, D3 Oral supplement; Device · Dietary Supplement
Lead sponsor: Madigan Army Medical Center; Federal
Eligibility: 18 Years to 69 Years
Enrollment: 106 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: Tacoma, Washington

Conditions: Knee Osteoarthritis, Knee Arthropathy, Surgery
Interventions: Personalized outcome prediction tool + targeted interventions, Standard of Care TKA; Behavioral
Lead sponsor: The Cleveland Clinic; Other
Eligibility: 18 Years to 80 Years
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Brain and Central Nervous System Tumors
Interventions: VEGF inhibitor PTC299; Drug
Lead sponsor: Pediatric Brain Tumor Consortium; Network
Eligibility: 3 Years to 21 Years
Enrollment: 28 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2015
U.S. locations: 8
States / cities: San Francisco, California • Washington D.C., District of Columbia • Chicago, Illinois + 5 more

Conditions: Low-grade Glioma
Interventions: DAY101; Drug
Lead sponsor: Karen D. Wright, MD; Other
Eligibility: 1 Year to 25 Years
Enrollment: 44 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2025
U.S. locations: 15
States / cities: Los Angeles, California • San Diego, California • San Francisco, California + 10 more

Conditions: Violence, Physical, Maltreatment, Child
Interventions: Pathways to Potential; Other
Lead sponsor: University of Michigan; Other
Eligibility: 18 Years and older
Enrollment: 111 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2026
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Breast Lumpectomy, Laparoscopic Cholecystectomy, Inguinal Hernia Repair
Interventions: Active de-Implementation; Behavioral
Lead sponsor: University of Michigan; Other
Eligibility: 18 Years and older
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: neurofibromatosis1 (NF1), Recurrent or Progressive Optic Pathway Gliomas (OPG), Recurrent or Progressive Low-grade Glioma
Interventions: Sorafenib (Nexavar); Drug
Lead sponsor: NYU Langone Health; Other
Eligibility: 2 Years and older
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 1
States / cities: New York, New York

Conditions: Pro-opiomelanocortin (POMC) Deficiency Obesity
Interventions: Setmelanotide, Placebo; Drug
Lead sponsor: Rhythm Pharmaceuticals, Inc.; Industry
Eligibility: 6 Years and older
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 1
States / cities: Scottsdale, Arizona

Conditions: Prostate Cancer, Prostate Disease
Interventions: Nivolumab, Brachytherapy, External Beam Radiation Therapy, Androgen Deprivation Therapy; Drug · Radiation
Lead sponsor: H. Lee Moffitt Cancer Center and Research Institute; Other
Eligibility: 18 Years and older · Male only
Enrollment: 44 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2026
U.S. locations: 1
States / cities: Tampa, Florida

Conditions: Advanced Malignant Solid Neoplasm, Ann Arbor Stage III Childhood Non-Hodgkin Lymphoma, Ann Arbor Stage IV Childhood Non-Hodgkin Lymphoma, Recurrent Childhood Central Nervous System Neoplasm, Recurrent Childhood Non-Hodgkin Lymphoma, Recurrent Malignant Solid Neoplasm, Recurrent Neuroblastoma, Refractory Malignant Solid Neoplasm, Refractory Neuroblastoma, Refractory Non-Hodgkin Lymphoma, Refractory Primary Central Nervous System Neoplasm
Interventions: Laboratory Biomarker Analysis, Selumetinib, Selumetinib Sulfate; Other · Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 12 Months to 21 Years
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2024
U.S. locations: 108
States / cities: Birmingham, Alabama • Mesa, Arizona • Phoenix, Arizona + 84 more

Conditions: Type 1 Diabetes
Interventions: Psychoeducation to reduce diabetes distress and improve glycemic outcomes; Behavioral
Lead sponsor: Joslin Diabetes Center; Other
Eligibility: 14 Years to 25 Years
Enrollment: 217 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 2
States / cities: Palo Alto, California • Boston, Massachusetts

Conditions: Bardet Biedl Syndrome (BBS), Alström Syndrome (AS)
Interventions: Setmelanotide, Placebo; Drug
Lead sponsor: Rhythm Pharmaceuticals, Inc.; Industry
Eligibility: 6 Years and older
Enrollment: 52 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2021
U.S. locations: 6
States / cities: San Diego, California • Springfield, Massachusetts • New York, New York + 3 more

Conditions: Obesity
Interventions: Metabolic & Bariatric Surgery; Procedure
Lead sponsor: Pennington Biomedical Research Center; Other
Eligibility: 35 Years to 60 Years · Female only
Enrollment: 11 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2026
U.S. locations: 1
States / cities: Baton Rouge, Louisiana

Conditions: Metastatic Hormone-sensitive Prostate Cancer (mHSPC)
Interventions: Xaluritamig, Darolutamide, Abiraterone; Drug
Lead sponsor: Amgen; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2030
U.S. locations: 8
States / cities: San Francisco, California • Boston, Massachusetts • Minneapolis, Minnesota + 5 more

Conditions: Pulmonary Arterial Hypertension
Interventions: Protein Elisa analysis, microRNA analysis, whole exome sequencing; Diagnostic Test
Lead sponsor: Medical College of Wisconsin; Other
Eligibility: 2 Years to 17 Years
Enrollment: 40 participants
Timeline: 2020 – 2023
U.S. locations: 1
States / cities: Milwaukee, Wisconsin

Conditions: Hodgkin Disease
Interventions: Nivolumab, brentuximab vedotin, bendamustine; Biological
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 5 Years to 30 Years
Enrollment: 72 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2024
U.S. locations: 43
States / cities: Birmingham, Alabama • Phoenix, Arizona • Loma Linda, California + 40 more

Conditions: Retinopathy of Prematurity, Neurodevelopmental Disorders, Macular Edema
Interventions: Swept Source OCT, Magnetic Resonance Imaging, Scavenged blood collection; Device · Other
Lead sponsor: Duke University; Other
Eligibility: 30 Weeks and older
Enrollment: 191 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2021
U.S. locations: 4
States / cities: Gainesville, Florida • St Louis, Missouri • Durham, North Carolina + 1 more

Conditions: Low Grade Glioma, High Grade Glioma
Interventions: Trametinib and Nivolumab, Dabrafenib, trametinib, nivolumab; Drug
Lead sponsor: Ann & Robert H Lurie Children's Hospital of Chicago; Other
Eligibility: 1 Year to 26 Years
Enrollment: 27 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 3
States / cities: Washington D.C., District of Columbia • Chicago, Illinois • New York, New York

Conditions: Adolescent Alcohol Use
Interventions: Brief Motivational Interviewing-based Alcohol Intervention, Smartphone App-delivered Mindfulness Training; Behavioral
Lead sponsor: Johns Hopkins University; Other
Eligibility: 12 Years to 17 Years
Enrollment: 1,500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2030
U.S. locations: 13
States / cities: Baltimore, Maryland • Belcamp, Maryland • Bowie, Maryland + 6 more

Conditions: Head and Neck Cancer, Squamous Cell Carcinoma of the Head and Neck
Interventions: Pembrolizumab, Placebo; Drug
Lead sponsor: University of Chicago; Other
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2025
U.S. locations: 4
States / cities: Atlanta, Georgia • Chicago, Illinois • Philadelphia, Pennsylvania

Search by objective public record fields.

Phase II Study of Olaparib and Pembrolizumab in Advanced Melanoma With Homologous Recombination (HR) Mutation

Vitamin D Supplementation in RNA-seq Profiles of Single-core Prostate Samples, Among Veterans

Combination Chemotherapy With or Without Etoposide Followed By an Autologous Stem Cell Transplant in Treating Young Patients With Previously Untreated Malignant Brain Tumors

Study of Normal Intestinal Development and Disease in Premature and Term Neonates

Comparing a Novel Phototherapy Kiosk to Oral Vitamin D Supplementation

Improving Total Knee Arthroplasty Dissatisfaction Through a Personalized Approach Focusing on PROMs Phenotypes

PTC299 in Treating Young Patients With Refractory or Recurrent Primary Central Nervous System Tumors

DAY101 In Gliomas and Other Tumors

Evaluating a School-based Social and Material Needs Identification System to Prevent Youth Violence Involvement

De-Implementation of Low-value Testing in Patients Undergoing Low-Risk Surgery

Sorafenib in Children and Young Adults With Recurrent or Progressive Low-Grade Astrocytomas

Setmelanotide for the Treatment of Early-Onset Pro-Opiomelanocortin (POMC) Deficiency Obesity

Combination of Nivolumab Immunotherapy With Radiation Therapy and Androgen Deprivation Therapy

Selumetinib Sulfate in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Activating MAPK Pathway Mutations (A Pediatric MATCH Treatment Trial)

Healthy And Positive Pathways for Young People With Type 1 Diabetes (HAPPY T1D)

Setmelanotide (RM-493), Melanocortin-4 Receptor (MC4R) Agonist, in Bardet-Biedl Syndrome (BBS) and Alström Syndrome (AS) Participants With Moderate to Severe Obesity

The Effects of Metabolic & Bariatric Surgery on Lipid Metabolism, Myeloid-Derived Suppressor Cells, and Cancer Cell Biology

Study Evaluating the Safety, Tolerability, and Efficacy of Xaluritamig in Combination With Androgen Receptor Pathway Inhibitors in Participants With Metastatic Hormone-sensitive Prostate Cancer

Assessment of the TGF-beta Pathway and Micro-RNA in Pediatric Pulmonary Arterial Hypertension

A Study of Nivolumab Plus Brentuximab Vedotin in Patients Between 5 and 30 Years Old, With Hodgkin's Lymphoma (cHL), Relapsed or Refractory From First Line Treatment

Analyzing Retinal Microanatomy in ROP

MAPK Inhibition Combined With Anti-PD1 Therapy for BRAF-altered Pediatric Gliomas

Brief Motivational Interviewing +/- Mindfulness Training for Adolescent Alcohol Use in Pediatric Primary Care

A Randomized, Double-Blind Phase II Study of Adjuvant Pembrolizumab Versus Placebo in Head and Neck Cancers at High Risk for Recurrence- the PATHWay Study